Genbase Biotechnology unveils innovative new drug research for
treatment of gastric/pancreatic cancer and solid tumors
ATLANTA–(BUSINESS WIRE)–Aiming to help accelerate progress in the global battle against cancer,
Shanghai Genbase Biotechnology Co. Ltd. (Genbase) was one of Shanghai’s
89 top biotechnology innovators showcasing their leading-edge research
at the American Association for Cancer Research (AACR) Annual Meeting
2019 in Atlanta, Georgia last week. Of the accepted poster
presentations, 40 were on promising targets for tumor immunotherapy —
antibodies targeting CD47, PDL-1, and CLDN18.2. Genbase’s work, along
with other Shanghai-based biotech companies, reflect the metropolis’
rise as a hub for oncology research and solutions to address underlying
causes of cancer growth and spread.
This prestigious annual AACR event covers the latest discoveries in
cancer research and highlights the work of the best minds from
institutions and hospitals around the world. This year’s meeting, which
took place March 29 to April 3, drew more than 20,000 attendees from 60
countries. Of the 386 poster presentations from China, close to a
quarter hail from Shanghai.
A wholly-owned subsidiary of Shanghai Genechem, and a company at the
forefront of gene research, Genbase epitomizes Shanghai’s top
biotechnology firms. At the conference, Genbase scientists presented two
posters describing their efforts to revolutionize pre-clinical
development of cancer treatments. Featured work showed data from novel
models that enable precise evaluation of new cancer therapeutics,
including T-cell therapies and targeted cancer immunotherapies.
“Cancer is a disease that has inflicted and killed too many people,
regardless of nationality, race, or religion,” said Dr. Jijun Yuan, CEO
of Genbase. “With gastric/pancreatic cancers and solid tumors ranking as
some of the most deadly, our scientific team has taken a big step
forward to fully understand various antibodies and how adding different
types of immunotherapy shows promise for treating these global killers.
We are thrilled to be able to present our findings at AACR 2019.”
Below are brief descriptions on Genbase’s two poster presentations:
-
“High Affinity Anti-CLDN18.2 Antibody for the Treatment of
Gastric/Pancreatic Cancer”:
Researchers developed a new
antibody which had a much higher affinity (30—50 times) and tumor
killing activity than the currently clinical leading antibody
Zolbertuximab. With gastric and pancreatic cancer some of the most
difficult types of cancer to treat, the new antibody may provide a
breakthrough solution since it is more stable in clinical practice,
more affinitive and more suitable for the treatment of these two
cancers.
-
“TCR mimetic antibody targeting HLA & NY-ESO-1 complex in cancer
therapy”:
Here scientists focused on CAR-T and TCR-T cell
therapies. Cell-based immunotherapies have proven to be one of the
most groundbreaking developments in oncology. But making CAR-T work in
the more common solid tumors — breast, lung, colon, and the like —
requires a lot more work because of the tumors’ immunosuppressive
microenvironment and tumor heterogeneity. Scientists discovered a
natural antibody, 7AI, that can effectively target HLA & peptide
complex of solid tumors, making it possible to target soluble targets
by CAR-T in solid tumors.
“Worldwide, and especially in China, cancer incidence and mortality have
been on the rise, and it has become a major factor in social
instability,” said Yuan. “We are committed to the use of genome-wide
analysis to conduct in-depth research on malignant tumors and to develop
solutions for resistance as well as new targeted drugs and tumor immune
pharmaceuticals.”
About Shanghai Genechem & Shanghai Genbase Biotechnology
Founded in 2002, Shanghai Genechem is China’s leading company in gene
technology services, research and development with more than 500
scientists. In the past 17 years, Genechem has closely worked with 7,000
clinical scientists on 11 cancer research fields in more than 400
tertiary hospitals across the country. Genbase, one of Genechem’s
subsidiaries, is an innovative immunotherapy company focusing on
developing cutting-edge gene, antibody and cellular therapies to address
tremendous unmet medical needs in China and globally.
Contacts
Sharon Y. Sim
SKC, Inc.
(415) 420-1889
sharon@skc-pr.com